The Role of the Interleukin-1–Receptor Antagonist in Blocking Inflammation Mediated by Interleukin-1

Publisher Website
Google Scholar
Abstract
Approaches involving the blockade of inflammatory cytokines such as interleukin-1 and tumor necrosis factor α (TNF-α) are entering mainstream clinical medicine: antibodies against TNF-α and soluble receptors for TNF-α are being used to treat rheumatoid arthritis and Crohn's disease. A large number of preclinical studies form the scientific basis for these anticytokine-based therapies. In experiments in animals in which a disease involving several cytokines has been induced, administration of neutralizing antibodies or the use of other means to block the biologic activity of a specific cytokine attenuates the effects of the disease or halts its progression.A novel approach to . . .